Press releases

2021  |  2020  |  2019  |  2018  |  All
January 19, 2021
Compass Therapeutics to Participate in the B. Riley Securities Virtual Oncology Investor Conference
September 15, 2020
Compass Therapeutics, Inc. Provides Corporate Update
August 24, 2020
Compass Therapeutics Announces Publication in the Journal Science of Preclinical Data Supporting the Potential of CTX-2026, a Novel Antibody to the Butyrophilin BTN3A1, in Ovarian Cancer Tumor Models

Presentations and publications

View all
March 12, 2020 | JCI Insight
Differentiated agonistic antibody targeting CD137 eradicates large tumors without hepatotoxicity
November 12, 2019 | SITC 2019
CTX-8371, a Novel Bispecific Targeting both PD-1 and PD-L1, is more Potent than Combination anti-PD-1 and PD-L1 Therapy and Provides Enhanced Protection from Tumors in vivo
November 12, 2019 | SITC 2019
A novel class of Innate Cell Engagers targeting NKp30

In the news

View all
September 17, 2020
Checkpoint Inhibitor CTX-2026 Shows Promising Efficacy in Preclinical Study
August 20, 2020
Ayala Pharmaceuticals Announces the Appointment of Vered Bisker-Leib, Ph.D. To Its Board of Directors
April 6, 2020
Compass Therapeutics’ immuno-oncology prospect clears solid tumors in mice